1454651-62-7 Usage
Molecular structure
A complex organic compound with a piperazine moiety, an ethanol group, an amino group, a methoxy group, and a tetrahydrobenzoannulene ring.
Piperazine moiety
A heterocyclic compound with a nitrogen atom at each end of the ring, which is known to exhibit various pharmacological activities.
Ethanol group
An alcohol group (-OH) attached to a carbon chain, which may influence the compound's solubility and bioavailability.
Amino group
A functional group (-NH2) that can participate in hydrogen bonding and may contribute to the compound's pharmacological properties.
Methoxy group
An alkoxy group (-OCH3) that is attached to the aromatic ring, which can influence the compound's lipophilicity and may affect its pharmacokinetic properties.
Pharmaceutical applications
Potential uses in the development of medications due to the pharmacological activities of piperazine derivatives, such as antipsychotic and antihistaminic properties.
Further research needed
Additional studies and investigations are required to fully understand the compound's potential uses, effects, and mechanisms of action.
Check Digit Verification of cas no
The CAS Registry Mumber 1454651-62-7 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,4,5,4,6,5 and 1 respectively; the second part has 2 digits, 6 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1454651-62:
(9*1)+(8*4)+(7*5)+(6*4)+(5*6)+(4*5)+(3*1)+(2*6)+(1*2)=167
167 % 10 = 7
So 1454651-62-7 is a valid CAS Registry Number.
1454651-62-7Relevant articles and documents
Development of a Process Route to the FAK/ALK Dual Inhibitor TEV-37440
Allwein, Shawn P.,Mowrey, Dale R.,Petrillo, Daniel E.,Reif, James J.,Purohit, Vikram C.,Milkiewicz, Karen L.,Bakale, Roger P.,Christie, Michael A.,Olsen, Mark A.,Neville, Christopher J.,Gilmartin, Gregory J.
, p. 740 - 747 (2017/06/05)
The development of a scalable route to TEV-37440, a dual inhibitor of focal adhesion kinase (FAK) and anaplastic lymphoma kinase (ALK), is presented. The medicinal chemistry route used to support this target through nomination is reviewed, along with the
FUSED BICYCLIC 2,4-DIAMINOPYRIMIDINE DERIVATIVE AS A DUAL ALK AND FAK INHIBITOR
-
, (2013/09/26)
The present invention provides a compound of formula (I) or a salt form thereof. The compound of formula (I) has ALK and FAK inhibitory activity, and may be used to treat proliferative disorders.
